Anonymousabout 5 hours ago
DM199 (rinvecalinase alfa), a recombinant human tissue kallikrein protein originally developed for stroke, has produced statistically significant blood pressure reductions and improved placental blood flow in a Phase 2 trial for pre-eclampsia — a condition that kills over 70,000 mothers annually and has no disease-modifying treatment. But with the trial limited to a single site in South Africa, years of regulatory hurdles ahead, and a long history of failed candidates in this space, the gap between laboratory promise and real-world access for the women who need it most remains wide.